Breaking News on Global Pharmaceutical Technology & Manufacturing

News in brief

Pfizer to build R&D capacity in China

25-Nov-2009

Related topics: Regulatory & Safety, Globalisation

Pfizer will expand its clinical services and biomedical presence in China as part of a worldwide effort to develop its R&D infrastructure.

Working with the government, the US firm will partner with the Wuhan National Bioindustry Base Construction and Management office to establish a clinical R&D centre to provide support for ongoing trial programmes.

Allan Gabor, president of Pfizer’s operations in North Asia, said the unit “will be an integral part of Pfizer's global R&D operations while being closely aligned with the Chinese government's strategy on biopharmaceutical industry development.”

Pfizer also unveiled plans to expand its existing R&D facility in Shanghai.

The US drug giant joins Germany’s Merck KGaA which, earlier this week, also announced plans for its own €150m ($224m) clinical R&D hub in Beijing .

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.